Literature DB >> 20813549

Phosphorylated endothelial NOS Ser1177 via the PI3K/Akt pathway is depressed in the brain of stroke-prone spontaneously hypertensive rat.

Hisae Yoshitomi1, Qiang Xu, Ming Gao, Yukio Yamori.   

Abstract

Stroke-prone spontaneously hypertensive rats (SHRSP) demonstrate impaired endothelium-dependent relaxation and often develop brain injuries. We investigated whether the regulatory mechanism for endothelial NOS (eNOS) phosphorylation and activation is altered in the cerebral cortex of SHRSP at a younger age. Western blot analysis revealed a low ratio of phosphor-eNOS (Ser1177) to total eNOS in SHRSP at 10 weeks of age. In addition, urinary nitric oxide metabolites (ie, nitrate and nitrite) were decreased compared with normal control WKY rats. Likewise, Akt phosphorylation (especially Ser473) was significantly reduced, with no changes in total Akt. Furthermore, the amount of the phosphatidylinositol 3-kinase (PI3K) was upstream of Akt was diminished, although attenuation of the PI3K/Akt pathway was not an effect of mTOR, another downstream target of Akt. Our findings indicate that abnormalities of the PI3K/Akt pathway in the cerebral cortex are involved in the impaired eNOS phosphorylation and activation in SHRSP.
Copyright © 2011 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20813549     DOI: 10.1016/j.jstrokecerebrovasdis.2010.01.014

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  8 in total

1.  Enhanced vascular PI3K/Akt-NOX signaling underlies the peripheral NMDAR-mediated pressor response in conscious rats.

Authors:  Marie A McGee; Abdel A Abdel-Rahman
Journal:  J Cardiovasc Pharmacol       Date:  2014-05       Impact factor: 3.105

2.  Tetramethylpyrazine analogue CXC195 ameliorates cerebral ischemia-reperfusion injury by regulating endothelial nitric oxide synthase phosphorylation via PI3K/Akt signaling.

Authors:  Shi Yan; Lin Chen; Xinbing Wei; Li Cheng; Lingjun Kong; Xinyong Liu; Xiumei Zhang; Huiqing Liu
Journal:  Neurochem Res       Date:  2014-11-27       Impact factor: 3.996

3.  A time course of NADPH-oxidase up-regulation and endothelial nitric oxide synthase activation in the hippocampus following neurotrauma.

Authors:  Mubeen A Ansari; Kelly N Roberts; Stephen W Scheff
Journal:  Free Radic Biol Med       Date:  2014-09-16       Impact factor: 7.376

4.  Salvinorin A preserves cerebral pial artery autoregulation after forebrain ischemia via the PI3K/AKT/cGMP pathway.

Authors:  H P Dong; W Zhou; X X Ma; Z Z He; Z H Wang
Journal:  Braz J Med Biol Res       Date:  2018-03-15       Impact factor: 2.590

5.  A Decrease of Brain MicroRNA-122 Level Is an Early Marker of Cerebrovascular Disease in the Stroke-Prone Spontaneously Hypertensive Rat.

Authors:  Rosita Stanzione; Franca Bianchi; Maria Cotugno; Simona Marchitti; Maurizio Forte; Carla Busceti; Larisa Ryskalin; Francesco Fornai; Massimo Volpe; Speranza Rubattu
Journal:  Oxid Med Cell Longev       Date:  2017-06-18       Impact factor: 6.543

6.  Mechanism of endothelial nitric oxide synthase phosphorylation and activation by tentacle extract from the jellyfish Cyanea capillata.

Authors:  Beilei Wang; Dan Liu; Chao Wang; Qianqian Wang; Hui Zhang; Guoyan Liu; Xia Tao; Liming Zhang
Journal:  PeerJ       Date:  2017-04-11       Impact factor: 2.984

7.  Xingnaojing Injection Protects against Cerebral Ischemia Reperfusion Injury via PI3K/Akt-Mediated eNOS Phosphorylation.

Authors:  Yue-Ming Zhang; Xiao-Yu Qu; Jing-Hui Zhai; Li-Na Tao; Huan Gao; Yan-Qing Song; Si-Xi Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2018-08-08       Impact factor: 2.629

8.  Sulforaphane Regulates eNOS Activation and NO Production via Src-Mediated PI3K/Akt Signaling in Human Endothelial EA.hy926 Cells.

Authors:  Ying Zhang; Pham Ngoc Khoi; Bangrong Cai; Dhiraj Kumar Sah; Young-Do Jung
Journal:  Molecules       Date:  2022-08-24       Impact factor: 4.927

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.